CAJ | 학술논문

目的探讨甲状腺乳头状微小癌的治疗和预后.方法回顾性分析1990年1月1日-1999年12月31日间在中山大学肿瘤防治中心头颈科接受治疗的124例甲状腺乳头状微小癌的临床和随访资料,对其进行Kaplan-Meier法单因素分析和Cox比例模型多因素分析.结果 124例甲状腺乳头状微小癌患者10年和15年生存率分别为94.9%、92.5%;单因素分析提示首诊时年龄≥35岁、有远处转移显著影响甲状腺乳头状微小癌患者的预后(均P＜0.05).而性别、是否为术中偶然发现、原发癌灶大小、淋巴结转移、是否为术后复发、手术范围等与患者预后无显著相关;多因素分析发现患者年龄≥35岁是影响甲状腺乳头状微小癌预后的独立因素(P=0.045).结论甲状腺乳头状微小癌患者预后较好,但年龄≥35岁或有远处转移者预后较差.
목적 탐토갑상선유두상미소암적치료화예후.방법 회고성분석1990년1월1일-1999년12월31일간재중산대학종류방치중심두경과접수치료적124례갑상선유두상미소암적림상화수방자료,대기진행Kaplan-Meier법단인소분석화Cox비례모형다인소분석.결과 124례갑상선유두상미소암환자10년화15년생존솔분별위94.9%、92.5%;단인소분석제시수진시년령≥35세、유원처전이현저영향갑상선유두상미소암환자적예후(균P＜0.05).이성별、시부위술중우연발현、원발암조대소、림파결전이、시부위술후복발、수술범위등여환자예후무현저상관;다인소분석발현환자년령≥35세시영향갑상선유두상미소암예후적독립인소(P=0.045).결론 갑상선유두상미소암환자예후교호,단년령≥35세혹유원처전이자예후교차.
Objective To investigate the treatment and prognosis of patients with papillary thyroid microcarcinoma. Methods The clinical and following-up data of 124 patients with papillary thyroid microcarcinoma treated at the Department of Head and Neck Surgery of Cancer Centre, SUN Yat-sen University from Jan 1990 to Dec 1999 were analyzed retrospectively for mortality and survival rate ( KaplanMeier). A multivariate analysis was performed in these patients by Cox proportional hazard model. Results The overall 10-year and 15-year survival rate of all 124 patients with papillary thyroid microcarcinoma were 94.9% and 92.5% respectively. The univariate analysis showed the prognostic factors significantly influencing the survival of patients included age (being worse for those of 35 years and older) at presentation, and the status of distant metastasis ( all P ＜ 0. 05 ) , while gender, incidentally found at surgery, the size of primary tumor, the status of neck lymph node metastasis, recurrence after a primary resection, and the extent of surgical resection did not significantly effect the prognosis. Multivariate analysis showed the age more than 35 years at presentation was an independent risk factor indicating worse prognosis (P = 0. 045 ). Conclusioas The prognosis of patients with papillary thyroid microcarcinoma is satisfactory, but that is poor for those patients 35 years old and up at presentation and with distant metastasis.